Aug. 19 at 11:24 AM
$IGC The setup is getting very interesting. Phase 2 CALMA is nearing completion, enrollment has already exceeded the original target, and Q4 2026 topline results are the major catalyst.
While the market is focused on the noise, I’m focused on the execution, the clinical catalyst, and the potential re-rating if IGC-AD1 delivers meaningful results. Add the AI/data platform, regulatory preparation, insider debt conversion, and a relatively small valuation—and the risk/reward starts getting interesting.
This isn’t about hype; it’s about the catalyst ahead. If Phase 2 hits,
$IGC could go from overlooked micro-cap to a serious biotech story very quickly. Shorts may be watching the chart, but bulls are watching the data 🚀🔥
Management has put
$1.5 million on the line, showing strong confidence and alignment heading into the catalyst
$NUVB $SYRE *
$IMNM *
$INTS
Updates released one day ago
https://youtu.be/ger_p3eVdQ0?is=L8PItIi_MIslLlvG
